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Introduction
Although the exact etiologic factors of obstructive sleep apnea syndrome (OSAS) have not been clea rly elicited, it is well recognized that disproportionate anatomy of the upper airway exists in OSAS, leading to obstruction during sleep.I·) The three major regions of obstruction are the nose, palate (pharynx), and base of tongue (hypopharynx). An anatomic obstruction at one or all of these levels can create increased airway resistance and contribute to nocturnal obstruction.
Surgical therapy using tracheotom y was the first treatment to manage OSAS in "Pickwickian" patients. Since the first tracheotomy was performed by Kuhle,' various procedures have been developed to alleviate anatomic obstruction in patients with OSAS. Current surgical therapy is directed to specific anatomic regions (table I) . There-fore, accurate presurgical evaluations are essential for the appreciation of the anatomic abnormality present. This allows for the utilization of a surgical protocol that results in improve d clinica l outcomes .
At our center, a thorough clinical head and neck evaluation in combinatio n with fiberoptic pharyngolaryngoscopy are performed to isolate and direct treatment at the region or regions of obstruction. A lateral cephalometric radiogra ph is also used to assist in treatment planning. Although cephalometric radiograp hy is only a static two-dimensional method of evaluating a dynamic three-dimensional area , it does provide useful information on the posterior airway space. The posterior airway space measurement on lateral cephalometric radiography has been shown to correlate with the volume of the hypopharyn geal airway on three-dimensional computed tomography.' In addition, it is a valuable study to assess the relationship of the maxillofacial skeleton and the hyoid bone to the airway (figure 1).
General indications for treatment
The consequences of OSAS include excess ive daytime sleepiness, seco ndary to sleep fragme ntation, and cardiovascular derangements that are manifested as hypoxemia, increased negative intrathoracic pressure, and autonomic nervous system alterations. These physiologic effects are associated with morbidity and mortality in OSAS. 6 -8 The general indications for surgery are well established (table 2) . A respiratory disturbance index (RDI) greater than or equal to 20 is used at our center as one of these parameters. It has been demonstrated that there is an increased risk of mortality at this level. In addition, most patients have excessive daytime sleepiness at this RDI level. It must be emphasized, however, that patients with an RDI of less than 20 and patients with upper airway resistance syndrome can experience significant sleep fragmentation and excessive daytime sleepiness; therefore, treatment should be considered.
Surgical treatment philosophy
Continuous positive airway pressure (CPAP) is considered the gold standard treatment modality. At our institution, we have established a surgical goal to define cure (table 3) . Adherence to this strict criteria enables us to compare our surgical results with CPAP results. A twophase surgical protocol was established that combines the evaluation, the indications for treatment, and the treatment philosophies to meet and better attain this goal (figure 2). A treatment plan is formulated by identifying the region or regions of obstruction and applying the specific surgical procedure to alleviate the obstruction(s). This two-phase approach was established to minimize surgical interventions and avoid unnecessary surgery while achieving a cure. After the completion of phase I surgery, Volume 78, Number 11 patients are given 4 to 6 months to heal before a postoperative polysomnogram is obtained to evaluate their outcome. Patients whose sleep apnea persists are offered phase II surgery (maxillomandibular advancement). It is important to review all possible treatment options and explain the rationale for this staged approach for upper airway reconstruction. In our opinion, combining phase I and phase II surgery is contraindicated because of the potential that phase II surgery might not be necessary and because of the increase in surgical morbidity and postoperative airway compromise. Our concern for postoperative airway compromise has prompted us to further establish a CPAP surgical protocol." Patients whose RDI is greater than or equal to 40 and whose oxygen desaturation is 80% or less are placed on CPAP therapy 2 weeks prior to surgery. These patients are maintained on CPAP postoperatively until 2 weeks before the followup polysomnogram (i.e ., 4-6 mo postoperatively). A temporary tracheotomy is considered for patients with severe sleep apnea (RDI: >60, Sa0 2 : <60) who are intolerant of nasal CPAP. 
Phase I surgery
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Patients should be instructed not to break or chew the tablet and to take it with a full lass of water see PRECAUTIONS: General, teotomy with genioglossus advancement, and hyoid myotomy and suspension. Nasal reconstruction and UPPP are designed to treat obstructions at the nasal and pharyngeal levels. The operative indications and techniques 2re well known, so they will not be reviewed again here. However, our preferred technique of pharyngeal reconstruction using the uvulopalatal flap has several advantages over conventional UPPP, and it will be described here.I0
Hypopharyngeal obstruction involves airway blockage at the tongue base and supraglottic regions. Because the mechanism of obstruction is complex, multiple procedures have evolved for the reconstruction of this region. They include mandibular osteotomy with genioglossus advancement and hyoid myotomy and suspension. The mandible, tongue, and hyoid complex plays a major role in OSAS at the hypopharyngeal level.l.2.'1 The rationale for surgical intervention at the tongue base is to minimize its collapse and posterior displacement during sleep. Anterior repositioning of the genioglossus muscle is achieved by a conservative mandibular osteotomy that advances the genial tubercle without moving the teeth or mandible. It improves the tension of the genioglossus muscle and decreases its collapsibility during sleep, thus alleviating obstruction. The rationale for altering the hyoid position in the treatment of tongue base obstruction is the fact that anatomically, the hyoid complex is an integral part of the hypopharynx. Anterior movement of the hyoid complex improves the posterior airway space, and numerous reports have supported the concept that surgical intervention at the hyoid level improves the hypopharyngeal airway.12-'S In 1984, we first described the inferior mandibular osteotomy with hyoid myotomy and suspension for hypopharyngeal reconstruction. 16 Our technique has evolved and been refined over the years in order to improve outcomes and minimize morbidity. The current technique of mandibular osteotomy with genioglossus advancement involves a limited osteotomy intraorally to isolate and advance the genial tubercle. It is a minimally invasive procedure that is routinely completed within 30 minutes.
Although hyoid myotomy with suspension also improves hypopharyngeal obstruction and is included in the phase I surgical protocol, it is not always performed simultaneously with genioglossus advancement. This is because most patients with OSAS have diffuse airway obstruction, and genioglossus advancement is generally combined with UPPP. The added insult to the infrahyoid region that is inflicted by combining the genioglossus advancement and the hyoid myotomy and suspension results in increased edema, and this is thought to be inappropriate in some patients. We have also found that in some patients, the hypopharyngeal airway obstruction can be treated with genioglossus advancement only, so a hyoid procedure is not always necessary. Furthermore, in some elderly patients (>60 yr), airway edema following simultaneous genioglossus advancement and hyoid myotomy and suspension can result in prolonged dysphagia that can require several days to resolve. For these reasons, we perform hyoid myotomy and suspension only in some patients and only as a separate surgical step. Mandibular osteotomy with genioglossus advancement. This procedure is designed to advance the tongue at the geni al tubercle attachment ( figure 4) . The surgery is limited in that the jaw and teeth do not move; only the genial tubercle is repositioned anteriorly. The limiting factor in this forward movement is the thickness of the mandibular symphysis. It must be emph asized that no additional room is anatomically created for the tongue in this procedure. The advancement of the genial tubercle increases the tension on the tongue muscu lature, thus limiting its posterior displacement dur- ing sleep. Preoperative radiographic analysis, including a lateral ceph a-Source: Sleep 1996;19:593-9. Reproduced with permi ssion. lometric radiograph and a panoramic dent al x-ray, are , -------------------------'A. necessary to assist the surgeon in surgical planning. The cephalometric radiograph will document skeletal deformitie s and soft tissue airway narrowing. It will further assist in the evaluation of anatomic and airway changes following surgery. The panoramic radiograph will demonstrate the course of the inferior alveolar nerve canal , the mental foramen, and the anatomy of the mandibular teeth . It will also detect any patho logic processes, such as periodontal dise ase and odontogenic cysts.
Su rg ica I procedures
The surgical procedure is performed completely intraorally. The muco sal incision is made just below the mucogingival junction, and a subperiosteal flap is reflected to expose the anterior mandible and mental nerve s. The genial tubercle and genioglossus muscle can be identified by finger palpation in the floor of the mouth and with the aid of the lateral ceph alometric radiograph. It is recommended that the superior horizontal bone cut be at least 5 mm below the root apices to minimize pare sthesia of the teeth . A minimum of 10 mm of the inferior borde r of the mandible should be preserved by proper placement of the inferior horizontal bone cut to reduce the risk of a pathologic mandibular fracture. The lateral and vertic al bone cuts are completed without extending beyond the canine teeth . Before the osteotomy is completed, a titanium screw is placed in the outer cortex to control and manipulate the genial tubercle fragment. Bleeding is controlled with electrocautery and a hemostatic agent , such as Gelfoam. The fragment is advanced and partially rotated to prevent retraction back into the floor of the mouth. The outer cortex and marrow are removed, and the inner cortex is rigidly fixed with a 2.0 mm titanium screw .
Hyoid myotomy and suspension. Our current technique involves suspending the hyoid to the superior thy- 
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• For use in emergency or specia l situations w hen space and electrica l sources may be limited . All patients are extubated while they are awake in the operating room immediately following surgery. All patients who undergo multiple procedures (UPPP combined with genioglossus advancement and/or hyoid myotomy and suspension) and all those who have significant coexisting medical conditions (hypertension, coronary artery disease) are monitored in the intensive care unit (lCU) on the first postoperative day. Nasal CPAP or humidified oxygen (35%) via a face tent are administered to all patients , and oximetry monitoring is performed throughout the hospitalization. Blood pressure is monitored closely, and hypertension is treated aggressively with intravenous antihypertensive medications to minimize postoperative bleeding and edema.
Although some authors have cautioned against the use of narcotics in OSAS patients who undergo surgery, 19, 20 we have not encountered any problems associated with the judicious use of narcotics for pain control. Our protocol includes intravenous morphine or meperidine administered by a nurse in graduated doses (e.g., 1-5 mg of morphine ql-3h as necessary) in the ICU, while the nurse monitors the respiratory rate. All nurses who care for OSAS patients must be educated about sleep apnea and the use of narcotics . Patients are transferred to the ward on the second postoperative day, and intramuscular meperidine and oxycodone elixir are administered. Oral hydrocodone is prescribed as a discharge medication. Discharge criteria include a stable airway, adequate oral intake of fluids , and satisfactory pain control. Patients are urged to use nasal CPAP following discharge; patients with severe OSAS who cannot tolerate nasal CPAP are prescribed humidified oxygen for 2 weeks.
* Genioglossus advancement and hyoid myotomy with suspension. roid cartilage ( figure 5 ).1 7The surgical approach is through a horizontal skin incision above the hyoid bone . The dissection is carried along the suprahyoid musculature to the body of the hyoid . The infrahyoid and suprahyoid muscles are partially dissected off to enable the advancement of the hyoid complex. Occasionally, the stylohyoid ligament must be amputated from the lesser cornu to improve the mobilization of the hyoid bone. It is important not to extend beyond the lesser cornu because of the risk to the superior laryngeal nerve. The hyoid is suspended anteriorly to the superior thyroid cartilage with four permanent sutures. It is recommended that a surgical drain be placed for 1 or 2 days to prevent seroma or hematoma formation. Since boththe Augmentin Z50 mg and500 mgtablets contain the sameamount of clavulanic acid (125 mg, as the potassium salt), 2 Augmentin Z50 mg tablets are not equivalentto 1 Augmentin500 mgtablet. Therefore, 2 Augmentin 250mgtablets shouldnot besubst ituted for 1 Augmentin500 mgtablel TheAugmentin Z50 mgtablet andthe 250mgchewabl e tablet do notcontainthesameamount of clavulanic acid (as the potassium salt). The Augmentin Z50 mg tablet contains 125mg of clavulanic acid, whereas the 250 mg chewable tablet contains 62.5 mg of clavulanic acid.
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Neonates and infants aged< 12weeksf1 month51
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